GENE ONLINE|News &
Opinion
Blog

2021-09-06| Trials & Approvals

BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer

by Rajaneesh K. Gopinath
Share To
On September 1st, BeiGene announced that the FDA has greenlit its Brukinsa (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) for treating adult patients with a rare type of lymphoma called Waldenström’s macroglobulinemia (WM).

This is Brukinsa's second FDA approval, after bagging authorization from the agency for treating Mantle Cell Lymphoma in 2019. Besides the US, the drug has received marketing approval in five countries for this indication. Before the latest FDA approval, Brukinsa was approved for treating WM in China and Canada.

GO Prime with only $1.49 now

LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!